Phathom Pharmaceuticals
PHAT
58 hedge funds and large institutions have $794M invested in Phathom Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 24 reducing their positions, and 5 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
10% more capital invested
Capital invested by funds: $719M → $794M (+$74.8M)
0.74% less ownership
Funds ownership: 75.41% → 74.67% (-0.74%)
5% less funds holding
Funds holding: 61 → 58 (-3)
54% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 24
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.48M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$565K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$403K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
Greenspring Associates
Owings Mills,
Maryland
|
-$5.21M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.28M |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$983K |
| 4 |
B
BP
London,
United Kingdom
|
-$753K |
| 5 |
Rockefeller Capital Management
New York
|
-$572K |
PHAT Hedge Fund Activity: Q3 2020 in Review
58 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2020, worth a combined $794M — up 10% from $719M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHAT and 2 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $1.5M. The largest seller was Greenspring Associates, cutting an estimated $5.21M.
- 58 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2020, down from 61 in Q2 2020.
- Funds reported $794M of Phathom Pharmaceuticals stock for Q3 2020, up 10% quarter-over-quarter.
- 2 funds opened new Phathom Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of -3 holders.
- The largest Phathom Pharmaceuticals buyer in Q3 2020 was Vanguard Group, an estimated $1.5M added.
- The largest Phathom Pharmaceuticals seller in Q3 2020 was Greenspring Associates, an estimated $5.21M sold.
Based on aggregated 13F filings for Q3 2020.